drugset / Trial / NCT05790200
Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma
Phase 2
Unknown
30 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NaSingle-groupOpen-labelHealth-services research
Summary
This study is a phase II clinical study of Cadonilimab (AK104) combined with chemotherapy in the treatment of PD-1 inhibitor-resistant nasopharyngeal carcinoma.
Timeline
- Start
- 2023-04-01
- Primary completion
- 2025-09-22
- Completion
- 2025-09-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | 200 mg | — |